

RNS Number : 1132R
Online Biomedical Inc.
02 February 2026

2 February 2026

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave Up for 2025 "Product of the Year" Award

Ondine's Steriwave® Shortlisted as Finalist for Prestigious 2025 Bionow Product of the Year Award

Ondine Biomedical Inc. (AIM: OBI) is proud to announce that its pioneering nasal photodisinfection technology, Steriwave®, has been shortlisted as a finalist for the Product of the Year Award at the 2025 Bionow Awards.

The Bionow Awards are a landmark event in the life sciences calendar, recognizing excellence, innovation, and world-class impact. This year's award process was record-breaking, with a 50% increase in nominations, making the shortlisting of Steriwave a significant testament to its clinical and commercial momentum within the UK healthcare landscape.

Steriwave uses a patented light-activated antimicrobial process to eliminate pathogens in the nose—a primary reservoir for bacteria that cause surgical site infections (SSIs). This non-antibiotic approach is critical in the global effort toward better antimicrobial stewardship.

Ondine's journey to this shortlisting has been bolstered by key clinical partnerships in the UK. The company is exceptionally pleased to acknowledge the early and steadfast support of the Innovation Team at Mid Yorkshire Teaching NHS Trust, led by Dr. Stuart Bond, and the clinical team led by Dr. Simon Jones, the first to adopt Steriwave into clinical practice in the UK, and the early clinical work of NHS Guy's and St. Thomas's ENT team led by Professor Claire Hopkins, whose studies with Steriwave demonstrated better outcomes for ENT patients including significant reductions in antibiotic use. These teams were instrumental in recognizing and proving the clear benefits of this non-antibiotic approach to infection control and patient safety as well as addressing antibiotic stewardship.

Carolyn Cross, CEO of Ondine Biomedical, commented:

"With so many hospitals confirming significant results, including SSI and mortality rate reductions and cost savings, we are grateful for the recognition to shine more light on the big impact photodisinfection-pioneered by Emeritus Professor Michael Wilson of University College London—has on both patients and healthcare systems that serve them. We are particularly grateful for the vision of the teams at Mid Yorks, who truly ran with this technology to advance antibiotic stewardship."

The nomination for Product of the Year—sponsored by Health Innovation Manchester, Health Innovation Yorkshire & Humber, and Health Innovation North West Coast—underscores the growing adoption of Steriwave as a standard of care for preventing post-operative complications and reducing healthcare costs and recovery times.

The winners will be announced at the Bionow Awards dinner on 5 March 2026, at the Concorde Conference Centre in Manchester.

Enquiries:

Ondine Biomedical Inc.

Carolyn Cross, CEO

www.ondinebio.com

+1 604 669 0555

or via Vane Percy & Roberts

Strand Hanson Limited (Nominated & Joint Financial Adviser)

James Harris, Richard Johnson

+44 (0)20 7409 3494

Peel Hunt LLP (Broker & Joint Financial Adviser)

James Steel, Dr. Chris Golden

+44 (0)20 7418 8900

Vane Percy & Roberts (Media Contact)

Simon Vane Percy

+44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRABGGDBCXDLG